Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Neuropace Inc (NPCE)
Upcoming IPO
Agiliti, Inc (AGTI)
Treace Medical Concepts, Inc. (TMCI)
Latham Group, Inc. (SWIM)
Rain Therapeutics Inc. (RAIN)
Impel Neuropharma, Inc. (IMPL)
Ftc Solar, Inc. (FTCI)
Aveanna Healthcare Holdings Inc. (AVAH)
Endeavor Group Holdings (EDR)
The Fortegra Group, Inc. (FRF)
Privia Health Group, Inc. (PRVA)
Priced IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Infobird (IFBD)
Troika Media Group, Inc. (TRKA)
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
More companies

Connect Biopharma Holdings Limited (CNTB)

Sector - Healthcare

Price chart

-0.94%
Return from IPO

Company News

IPO Profile

About company

They are a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Their core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Their two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Their lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis, or AD, and asthma. Based on observed results in preliminary clinical studies, CBP-201 has the potential to be differentiated from dupilumab, an antibody that also targets IL-4Ra, which is now approved by the U.S. Food and Drug Administration, or FDA. They have initiated a Phase 2b trial of CBP-201 in the United States, Australia and New Zealand in AD patients with moderate-to-severe AD, and plan to initiate additional trials in asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, in the first half of 2021 and in AD patients in China in the second half of 2021. They anticipate reporting top-line results from their ongoing clinical trial in AD patients in the second half of 2021.
Industry
Pharmaceuticals
CEO CFO
Zheng Wei Eric Hall
Employees Founded
62 2012

Contacts

Address: Science And Technology Park, East R&d Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu, China 215400

Telephone: +86 512 5357 7866.

Web page: http://www.connectbiopharm.com

IPO information

First Trade Date 3/19/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 9.4
Shares Revised (MM) 11.3
Expected offer amount (MM) $150
Realized offer amount(MM) $192.1

Financial Data (last reporting year)

Market Cap (MM) $863.1
Revenues (MM) $-30.3
Net Income (Loss) (MM) $-119.4

Voting

What do you think will happen with the CNTB share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Jefferies

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Jefferies/ SVB Leerink/ Piper Sandler/ CICC
CO-Managers
-

Sector: Healthcare

Tweets about $CNTB

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats